BioStock: Stayble did not reach the primary endpoint in phase IIb

Stayble Therapeutics recently announced that the company’s phase IIb study did not meet the primary endpoint. The drug candidate STA363 did not show a statistically significant reduction in pain compared to placebo after 6 months. The company now plans to continue evaluating top-line data from the study to create a better understanding of the results. 

Read the full article at biostock.se:

https://www.biostock.se/en/2023/11/stayble-did-not-reach-the-primary-endpoint-in-phase-iib/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se